advertisement
Abstract #65926 Published in IGR 17-3
Seeing over the horizon - targeting the endocannabinoid system for the treatment of ocular disease
Cairns EA; Toguri JT; Porter RF; Szczesniak AM; Kelly MEJournal of basic and clinical physiology and pharmacology 2016; 27: 253-265
The observation that marijuana reduces intraocular pressure was made by Hepler and Frank in the 1970s. Since then, there has been a significant body of work investigating cannabinoids for their potential use as therapeutics. To date, no endocannabinoid system (ECS)-modulating drug has been approved for clinical use in the eye; however, recent advances in our understanding of the ECS, as well as new pharmacological tools, has renewed interest in the development of ocular ECS-based therapeutics. This review summarizes the current state-of-affairs for the use of ECS-modulating drugs for the treatment of glaucoma and ocular inflammatory and ischemic disease.
Full article
Classification:
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)
